New Pharmacologic Therapies for Gastroenteropancreatic Neuroendocrine Tumors

12Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Successful treatment of unresectable and metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) requires the thoughtful choice of systemic therapy as a component of a multidisciplinary therapeutic approach. The role of somatostatin analogues is established in symptom relief, but the efficacy of interferon and radiopeptide targeted therapy is not clear. The utility of a variety of tyrosine kinase and antiangiogenic agents is variable and under investigation, whereas the role of cytotoxic chemotherapy in poorly differentiated GEP-NETs is accepted. Overall, the ideal treatment of more indolent tumors is less certain. Reassessments of the GEP-NET pathology classification has provided improved logic for the role of a variety of agents, whereas the precise positioning of many new agents that target molecular pathways of angiogenesis and proliferation is under examination. This article describes the current options for systemic therapy for GEP-NETs within the framework of the current World Health Organization classification system. © 2010 Elsevier Inc.

Cite

CITATION STYLE

APA

Lawrence, B., Gustafsson, B. I., Kidd, M., & Modlin, I. (2010, September). New Pharmacologic Therapies for Gastroenteropancreatic Neuroendocrine Tumors. Gastroenterology Clinics of North America. https://doi.org/10.1016/j.gtc.2010.08.013

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free